Title |
An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions
|
---|---|
Published in |
BMC Pharmacology and Toxicology, August 2014
|
DOI | 10.1186/2050-6511-15-46 |
Pubmed ID | |
Authors |
M Mofizul Islam, Ian S McRae |
Abstract |
In an effort to control non-medical use and/or medical abuse of prescription drugs, particularly prescription opioids, electronic prescription drug monitoring programs (PDMP) have been introduced in North-American countries, Australia and some parts of Europe. Paradoxically, there are simultaneous pressures to increase opioid prescribing for the benefit of individual patients and to reduce it for the sake of public health, and this pressure warrants a delicate balance of appropriate therapeutic uses of these drugs with the risk of developing dependence. This article discusses pros and cons of PDMP in reducing diversion of prescription opioids, without hampering access to those medications for those with genuine needs, and highlights tensions around PDMP implementation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | 46% |
Australia | 3 | 23% |
United Kingdom | 1 | 8% |
Unknown | 3 | 23% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 69% |
Practitioners (doctors, other healthcare professionals) | 3 | 23% |
Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Norway | 1 | <1% |
Canada | 1 | <1% |
Unknown | 120 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 24 | 20% |
Researcher | 15 | 12% |
Student > Bachelor | 15 | 12% |
Other | 11 | 9% |
Student > Ph. D. Student | 10 | 8% |
Other | 22 | 18% |
Unknown | 25 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 26% |
Social Sciences | 12 | 10% |
Nursing and Health Professions | 9 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 7% |
Economics, Econometrics and Finance | 6 | 5% |
Other | 26 | 21% |
Unknown | 28 | 23% |